NovoRapid revenue trends

In 3Q17, Novo Nordisk’s (NVO) NovoRapid reported revenues of 5.0 billion Danish krone (or DKK), which reflected ~9% growth on year-over-year (or YoY) basis. In 3Q17, in the US, Europe, AAMEO (Asia, Africa, Middle East and Oceania), China, Japan & Korea, and Latin America, NovoRapid generated revenues of 2.7 million DKK, 1.1 million DKK, 559 million DKK, 307 million DKK, 227 million DKK, and 84 million DKK, respectively. In 3Q17, in the US, AAMEO, Europe, China, and Latin America, NovoRapid witnessed ~8%, 2%, 20%, 22%, and 58% growth on a YoY basis, respectively. Sales in Japan and Korea remained flat.

NovoRapid reported revenues for the first nine months of 2017 (or 9M17) of 15.4 billion DKK, which is ~8% growth on YoY basis. In the U.S., Europe, AAMEO, China, Japan & Korea and Latin America, NovoRapid generated 9M17 revenues of DKK 8.4 billion, DKK 3.2 billion, DKK 1.7 billion, DKK 952 million, DKK 699 million, and DKK 246 million, respectively.

How Did Novo Nordisk’s Modern Insulin Segment Perform in 3Q17?

Levemir revenue trends

In 3Q17, Novo Nordisk’s Levemir reported revenues of DKK 3.16 billion which reflected ~23% decline YoY basis.

In 3Q17, in the U.S., Europe, AAMEO, China, Japan & Korea and Latin America, Levemir generated revenues of DKK 2.0 billion, DKK 567 million, DKK 224 million, DKK 175 million, DKK 30 million and DKK 89 million, respectively. In 3Q17, in the U.S., AAMEO, Europe China, Japan& Korea and Latin America, Levemir witnessed ~32% decline, 12% decline, 9% growth, 26% growth, 19% decline and 52% growth on YoY basis.

Levemir reported 9M17 revenues of DKK 10.7 billion which is ~17% decline on YoY basis.

In the U.S., Europe, AAMEO, China, Japan & Korea and Latin America, Levemir generated 9M17 revenues of DKK 7.18 billion, DKK 1.8 billion, DKK 687 million, DKK 525 million, DKK 101 million, and DKK 257 million, respectively.

In 3Q17, Novo Nordisk’s peers in insulin market Eli Lilly (LLY), Sanofi (SNY) and MannKind Corporation (MNKD) reported revenues of $5.7 billion, $10.6 billion, and $2.0 million, respectively. Notably, Vanguard FTSE All-World ex-US ETF (VEU) invests ~0.37% of its total portfolio holding in Novo Nordisk.

In the next article, we will discuss the performance of Novo Nordisk’s Modern insulin NovoMix and human insulin.

Latest articles

On June 25, AbbVie (ABBV) announced that it plans to buy Allergan (AGN) for ~$63 billion. At 10:20 AM ET, Allergan stock rose 27%, while AbbVie stock fell 15%.

On June 25, Credit Suisse initiated its coverage on Shake Shack with an “outperform” rating and a target price of $77—an upside potential of 15.4% from its closing price of $66.72 on June 24.

On June 25, the soft economic data isn't an isolated case. We have been getting a flurry of dismal data points. The US economy added only 75,000 non-farm jobs in May.

French retail giant Carrefour has agreed to sell an 80% stake in its China operations for ~$705 million to Suning.com, an Alibaba (BABA) backed company. While China represents a massive opportunity with its almost 1.4 billion population, it has not been an easy market for foreign companies, at least when it comes to retail and e-commerce.

On June 25, US Secretary of Agriculture Sonny Perdue told CNN in an interview that the US-China trade war has impacted US farmers. He said that farmers “are one of the casualties” of the trade war.

25 Jun

Hang Seng and Nikkei 225 Lose amid Trade Worries

WRITTEN BY Mayur Sontakke, CFA, FRM

After rising marginally yesterday, Hong Kong’s Hang Seng Index fell today. The index lost 1.15% to end at 28,185.98. Only seven stocks in the index rose, while 39 declined. Four remained unchanged. Tencent Holdings (TCEHY) was one of the worst performers with a 1.8% fall.

172.31.16.229